Daratumumab Plus Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): Final Analysis of Griffin Among Clinically Relevant Subgroups

Autor: Chari, Ajai, Kaufman, Jonathan L., Laubach, Jacob P, Sborov, Douglas W, Reeves, Brandi, Rodriguez, Cesar, Silbermann, Rebecca, Costa, Luciano J., Anderson, Larry D., Nathwani, Nitya, Shah, Nina, Bumma, Naresh, Holstein, Sarah A., Costello, Caitlin, Jakubowiak, Andrzej, Wildes, Tanya M., Orlowski, Robert Z., Shain, Kenneth H., Cowan, Andrew J., Pei, Huiling, Cortoos, Annelore, Patel, Sharmila, Lin, Thomas S., Richardson, Paul G., Usmani, Saad, Voorhees, Peter M.
Zdroj: Blood; November 2022, Vol. 140 Issue: Supplement 1 p7278-7281, 4p
Databáze: Supplemental Index